TransMedics Inc., an Andover, Mass.-based developer of portable life support systems for organ transplants, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol TMDX, with Morgan Stanley serving as lead underwriter.
The company has raised around $90 million in total VC funding since 2000, including a $25.5 million Series D round earlier this year. Shareholders include 3i Group (24.4% pre-IPO stake), Tudor Investment Corp. (14.7%), Flagship Ventures (14.3%), VantagePoint Venture Partners (10%), Sherbrooke Partners (9.2%), Alta Partners (8.9%), CB Health Ventures (7.4%), Posco BioVentures and Sagamore Bioventures. www.transmedics.com